TPCA (Docetaxel, Cisplatin, Irinotecan, Bevacizumab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TPCA (Docetaxel, Cisplatin, Irinotecan, Bevacizumab), covering 2017-11-09 to 2017-11-09. Get the full timeline:
Most recent: Clinical Trial Update: Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer [Phase 2]